Research programme: PDGF inhibitors - Archemix

Drug Profile

Research programme: PDGF inhibitors - Archemix

Latest Information Update: 27 Apr 2007

Price : $50

At a glance

  • Originator Archemix Corporation
  • Class
  • Mechanism of Action Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 03 Aug 2004 Sirna has signed an agreement with Archemix to exclusively manufacture aptamers
  • 29 Jun 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top